You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
FDA concerns delay Xspray Pharma's Dasynoc approval again
Text:
Kim Liedholm | [email protected]
Xspray Pharma announces that the FDA's decision on market approval for Dasynoc is once again delayed due to GMP concerns at an external contract manufacturer. What was described last summer as a very good omen...